STAT Plus: Taking the measure of small-cap biotech: Bio-Path Holdings, CytoDyn
Bio-Path Holdings soared an astounding 700 percent over two trading sessions. CytoDyn has made astonishing claims. Tme for some due dilligence on both.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario